Enanta Pharma (ENTA) Tops Q4 EPS by 11c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018
November 26, 2018 4:01 PM ESTWebcast and Conference Call today at 4:30 p.m. ET
Royalty revenue for the quarter increased to $67.2 million Net income was $27.4 million, or $1.30 per diluted common share Cash and marketable securities totaled $325.1 million Phase 2a study initiated with EDP-938 against respiratory syncytial virus (RSV) infection in a human challenge study Hepatitis B virus (HBV) candidate EDP-514 selected for clinical development in 2019WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc.... More
